These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 15160950)

  • 1. Comparison of bone marrow aspirates and biopsies in pediatric patients with ALL at days 7 and 14 of induction therapy.
    Countouriotis A; Landaw EM; Naeim F; Moore TB; Sakamoto KM
    Leuk Lymphoma; 2004 Apr; 45(4):745-7. PubMed ID: 15160950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the cellularity and presence of residual leukemia in bone marrow aspirate and biopsy specimens in pediatric patients with acute lymphoblastic leukemia (ALL) at day 7-14 of chemotherapy.
    Kidd PG; Saminathan T; Drachtman RA; Ettinger LJ
    Med Pediatr Oncol; 1997 Dec; 29(6):541-3. PubMed ID: 9324341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implications of delayed bone marrow aspirations at the end of treatment induction for risk stratification and outcome in children with acute lymphoblastic leukaemia.
    Zuna J; Moericke A; Arens M; Koehler R; Panzer-Grümayer R; Bartram CR; Fischer S; Fronkova E; Zaliova M; Schrauder A; Stanulla M; Zimmermann M; Trka J; Stary J; Attarbaschi A; Mann G; Schrappe M; Cario G
    Br J Haematol; 2016 Jun; 173(5):742-8. PubMed ID: 26913693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prognostic value of both detection of lymphoblasts in the period of early treatment and minimal residual disease in childhood acute lymphoblastic leukemia].
    Tie LJ; Gu LJ; Song DL; Jiang LM; Xue HL; Tang JY; Dong L; Pan C; Chen J; Ye H; Wang YP; Chen J
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):6-9. PubMed ID: 15946500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia.
    Short NJ; Kantarjian HM; Sasaki K; Cortes JE; Ravandi F; Thomas DA; Garcia-Manero G; Khouri I; Kebriaei P; Champlin RE; Pierce S; Issa GC; Konopleva M; Kadia TM; Bueso-Ramos C; Khoury JD; Jain N; O'Brien SM; Jabbour E
    Cancer; 2016 Dec; 122(24):3812-3820. PubMed ID: 27508525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of multidimensional flow cytometry with standard morphology for evaluation of early marrow response in pediatric acute lymphoblastic leukemia.
    Meshinchi S; Thomson B; Finn LS; Leisenring W; Green C; Radich JP; Loken M; Hawkins D
    J Pediatr Hematol Oncol; 2001 Dec; 23(9):585-90. PubMed ID: 11902302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistence of lymphoblasts in bone marrow on day 15 and days 22 to 25 of remission induction predicts a dismal treatment outcome in children with acute lymphoblastic leukemia.
    Sandlund JT; Harrison PL; Rivera G; Behm FG; Head D; Boyett J; Rubnitz JE; Gajjar A; Raimondi S; Ribeiro R; Hudson M; Relling M; Evans W; Pui CH
    Blood; 2002 Jul; 100(1):43-7. PubMed ID: 12070006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Importance of the day 7 bone marrow biopsy as a prognostic measure of the outcome in children with acute lymphoblastic leukemia.
    Schultz KR; Massing B; Spinelli JJ; Gaynon PS; Wadsworth L
    Med Pediatr Oncol; 1997 Jul; 29(1):16-22. PubMed ID: 9142200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of early treatment response in children with acute lymphoblastic leukemia: a single institution experience in Shanghai, China.
    Tie LJ; Gu LJ; Song DL; Jiang LM; Xue HL; Tang JY; Dong L; Pan C; Chen J; Ye H; Chen J
    Zhongguo Dang Dai Er Ke Za Zhi; 2009 Jan; 11(1):5-9. PubMed ID: 19149913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bone marrow leukemic progenitor cell content in pediatric T-lineage acute lymphoblastic leukemia patients with an isolated extramedullary first relapse.
    Uckun FM; Gaynon PS; Stram DO; Sensel MG; Sarquis MB; Willoughby M
    Leuk Lymphoma; 2001 Jan; 40(3-4):279-85. PubMed ID: 11426549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia.
    Coustan-Smith E; Behm FG; Sanchez J; Boyett JM; Hancock ML; Raimondi SC; Rubnitz JE; Rivera GK; Sandlund JT; Pui CH; Campana D
    Lancet; 1998 Feb; 351(9102):550-4. PubMed ID: 9492773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of persistent peripheral blood and bone marrow lymphoblasts on day 15 of therapy in childhood acute lymphoblastic leukemia as detected by flow cytometry.
    Jaworska-Posadzy A; Styczynski J; Kubicka M; Debski R; Rafinska-Kurylo B; Kolodziej B; Pogorzala M; Wysocki M
    Anticancer Res; 2011 Apr; 31(4):1453-7. PubMed ID: 21508402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Residual bone marrow leukemic progenitor cell burden after induction chemotherapy in pediatric patients with acute lymphoblastic leukemia.
    Uckun FM; Stork L; Seibel N; Sarquis M; Bedros C; Sather H; Sensel M; Reaman GH; Gaynon PS
    Clin Cancer Res; 2000 Aug; 6(8):3123-30. PubMed ID: 10955793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone marrow fibrosis in childhood acute lymphoblastic leukemia correlates to biological factors, treatment response and outcome.
    Norén-Nyström U; Roos G; Bergh A; Botling J; Lönnerholm G; Porwit A; Heyman M; Forestier E
    Leukemia; 2008 Mar; 22(3):504-10. PubMed ID: 18094715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical importance of speed of response to therapy in childhood lymphoblastic leukaemia.
    Lilleyman JS
    Leuk Lymphoma; 1998 Nov; 31(5-6):501-6. PubMed ID: 9922040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment outcome of childhood standard-risk and median-risk acute lymphoblastic leukemia with CCLG-2008 protocol].
    Liu X; Zou Y; Wang H; Chen X; Ruan M; Chen Y; Yang W; Guo Y; Liu T; Zhang L; Wang S; Zhang J; Liu F; Cai X; Qi B; Chang L; Zhu X
    Zhonghua Er Ke Za Zhi; 2014 Jun; 52(6):449-54. PubMed ID: 25190166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Concept and interim result of the ALL-BFM 90 therapy study in treatment of acute lymphoblastic leukemia in children and adolescents: the significance of initial therapy response in blood and bone marrow].
    Schrappe M; Reiter A; Sauter S; Ludwig WD; Wörmann B; Harbott J; Bender-Götze C; Dörffel W; Dopfer R; Frey E
    Klin Padiatr; 1994; 206(4):208-21. PubMed ID: 7526027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of outcome by early response in childhood acute lymphoblastic leukemia.
    Möricke A; Lauten M; Beier R; Odenwald E; Stanulla M; Zimmermann M; Attarbaschi A; Niggli F; Schrappe M
    Klin Padiatr; 2013 May; 225 Suppl 1():S50-6. PubMed ID: 23700057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Minimal residual disease analysis in acute lymphoblastic leukemia of childhood within the framework of COALL Study: results of an induction therapy without asparaginase].
    zur Stadt U; Harms DO; Schlüter S; Jorch N; Spaar HJ; Nürnberger W; Völpel S; Gutjahr P; Schrappe M; Janka G; Kabisch H
    Klin Padiatr; 2000; 212(4):169-73. PubMed ID: 10994545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study.
    Pui CH; Pei D; Coustan-Smith E; Jeha S; Cheng C; Bowman WP; Sandlund JT; Ribeiro RC; Rubnitz JE; Inaba H; Bhojwani D; Gruber TA; Leung WH; Downing JR; Evans WE; Relling MV; Campana D
    Lancet Oncol; 2015 Apr; 16(4):465-74. PubMed ID: 25800893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.